STOCK TITAN
  1. Home
  2. News
  3. BRTX

BioRestorative Therapies Inc - BRTX STOCK NEWS

Welcome to our dedicated news page for BioRestorative Therapies (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioRestorative Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioRestorative Therapies's position in the market.

News
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Rhea-AI Summary
BioRestorative Therapies announces FDA clearance of Phase 2 BRTX-100 clinical study protocol amendment, replacing saline injections with sham injections in the control group. The amendment aims to enhance safety and prevent transient clinical outcomes, maintaining the 2024 enrollment completion target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
clinical trial
-
News
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Rhea-AI Summary
BioRestorative Therapies, Inc. announces collaboration with Galen Patient Recruitment, Inc. to accelerate patient enrollment in Phase 2 study of BRTX-100 for chronic lumbar disc disease. Recent enhancements triple monthly trial capacity, with enrollment expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
partnership clinical trial
-
News
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
Rhea-AI Summary
BioRestorative Therapies, Inc. announces the filing of a registration statement on Form S-1 with the SEC for the resale of up to 2,513,686 shares of common stock by selling securityholders. The filing covers shares issuable pursuant to previously issued warrants, with the registration statement not yet effective. The Company is not offering shares directly to the public at this time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
News
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
Rhea-AI Summary
BioRestorative Therapies, Inc. announced the filing of its Form 10-K annual report for 2023, highlighting its lead clinical-stage cell therapy candidate, BRTX-100, and ThermoStem® program. Positive preliminary data from the Phase 2 study of BRTX-100 in treating chronic lumbar disc disease was presented, showing encouraging results. The company also received four notices of allowance for its ThermoStem® program, indicating progress in patent approvals. Financially, BioRestorative reported a net loss decrease of 22% for 2023, with $11.07 million in cash, cash equivalents, and investments at year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
News
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
Rhea-AI Summary
BioRestorative Therapies, Inc. announces its participation in the 36th Annual ROTH Conference. The company's CEO will engage in a fireside chat and one-on-one meetings with investors. The event will be held from March 17-19, 2024, at the Ritz Carlton, Laguna Niguel in California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
News
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
Rhea-AI Summary
BioRestorative Therapies (BRTX) is advancing its lead candidate, BRTX-100, a cell-based therapy for chronic lumbar disc disease. The recent data presented at the ORS 2024 Annual Meeting showed positive trends in pain and function improvements. The therapy uses autologous stem cells manufactured in a low oxygen environment to mimic disc conditions. If successful, BRTX-100 could revolutionize disc-related pain treatment with its personalized, minimally invasive approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
News
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
Rhea-AI Summary
BioRestorative Therapies, Inc. announced agreements with certain holders of its existing warrants to exercise their warrants at a reduced price, generating approximately $8.1 million in gross proceeds. The reduction of the exercise price and issuance of new warrants was structured as an at-market transaction under Nasdaq rules. The new warrants will be exercisable into an aggregate of up to 2,513,685 shares of common stock, at an exercise price of $2.43 per share, and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.49%
Tags
none
-
News
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary 26 and 52-week blinded data from the ongoing Phase 2 clinical trial of their lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease. The data presented at the Orthopaedic Research Society 2024 Annual Meeting showed positive trends in pain and function scales compared to baseline, indicating meaningful signals in patients enrolled in the study. The company also reported no notable safety signals, and the FDA will use the data to determine whether the trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.21%
Tags
clinical trial
-
News
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary blinded data from the ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease. The data will be presented at the Orthopaedic Research Society 2024 Annual Meeting. BRTX-100 is a novel cell-based therapeutic evaluated for safety and efficacy in treating cLDD. The company will host a webcasted conference call to review the data on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.52%
Tags
conferences clinical trial
News
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
Rhea-AI Summary
BioRestorative Therapies, Inc. (BRTX) has been granted a notice of allowance for a U.S. patent related to the Company’s metabolic ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes. This will be the fourth U.S. patent granted under this particular patent family, covering methods of using differentiated human brown fat adipocytes to screen and identify compounds that can activate and regulate metabolic activity. The Company sees this as an important milestone, providing them with tools to screen large libraries of compounds targeting metabolic disorders such as obesity, potentially leading to the development of drugs targeting weight loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
Stock BRTX logo
BioRestorative Therapies Inc

Nasdaq:BRTX

BRTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BRTX Stock Data

8.87M
5.50M
18.8%
9.6%
0.6%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Melville

About BRTX

biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas